Related Experiment Video
Updated: Mar 12, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
Published on: June 3, 2018
Increasing healthcare costs: can we influence the costs of glaucoma care?
Marc Töteberg-Harms1, Michael S Berlin, Frances Meier-Gibbons
1aDepartment of Ophthalmology, University Hospital Zurich, Zurich, Switzerland bGlaucoma Institute of Beverly Hills, West Hollywood cUniversity of California Los Angeles Stein Eye Institute, Los Angeles, California, USA dEye Center Rapperswil, Rapperswil, Switzerland.
Insights
Improving patient adherence to glaucoma treatment is key to controlling rising healthcare costs. Further research comparing diagnostic and therapeutic strategies can help reduce expenses for this irreversible blindness condition.
Area of Science:
- Ophthalmology
- Health Economics
Background:
- Global healthcare costs are escalating, influenced by patient and physician factors.
- Glaucoma, a leading cause of irreversible blindness, necessitates chronic treatment with often low patient adherence.
- Treatment costs for glaucoma are a significant concern for patients and healthcare systems.
Purpose of the Study:
- To identify strategies for controlling the rising costs associated with glaucoma care.
- To review existing literature on factors influencing glaucoma treatment expenses.
- To explore potential solutions for cost reduction in managing glaucoma.
Main Methods:
- Systematic review of studies related to glaucoma care costs.
- Categorization of studies into diagnostic costs, treatment comparisons, patient factors, and general cost aspects.
- Analysis of theoretical models and calculations regarding healthcare expenses.
Main Results:
- Studies were categorized into diagnostic costs, treatment comparisons (drugs, laser, surgery), patient adherence, and theoretical cost models.
- Patient-related factors, particularly adherence, significantly impact treatment costs.
- Direct cost comparisons between different treatment modalities were examined.
Conclusions:
- Improving patient adherence to glaucoma treatment is a critical factor in reducing healthcare costs.
- Cross-country cost comparisons are challenging due to diverse healthcare systems and cultural factors.
- Further research, including theoretical models and patient studies, is needed to optimize diagnostic and therapeutic scenarios for cost reduction.
Purpose Of Review:
Despite a decrease in real average growth rates per capita since 2009, healthcare costs continue to rise worldwide. Numerous patient-related and doctor-related factors have contributed to this rise. Glaucoma is the leading cause of irreversible blindness and requires chronic, usually lifelong treatment. As with other chronic diseases, the adherence to prescribed treatment is often low and maybe influenced by the cost of the therapy. The purpose of this review is to seek potential solutions to best control the escalating costs of glaucoma care.
Recent Findings:
The studies we selected for this review can be divided into four different categories: costs of diagnostic tests; costs of direct comparisons between drugs or laser and conventional surgery; patient-related factors (such as adherence); and general aspects regarding costs: theoretical models and calculations.
Summary:
It is challenging to find reliable studies concerning this subject matter. As patients are under the umbrellas of variously organized healthcare systems which span different cultures, the costs between countries are difficult to compare. However, one common aspect to lower costs in glaucoma care is to improve patient adherence. Theoretical models with actual patient studies could enable cost reductions by comparing multiple diagnostic and therapeutic scenarios. VIDEO ABSTRACT: http://links.lww.com/COOP/A22.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Photoreceptors and Visual Pathways

